Clinical Trials Logo

Thyroid Cancer clinical trials

View clinical trials related to Thyroid Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06051747 Active, not recruiting - Thyroid Cancer Clinical Trials

Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea)

Start date: July 17, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial aims to assess the effectiveness and safety of a novel approach utilizing biopolymers, hydrogels, mucous membranes, and cartilage tissue regeneration cells integrated into 3D bioprinting technology for the creation and implantation of patient-specific tracheal organs.

NCT ID: NCT05796258 Active, not recruiting - Thyroid Cancer Clinical Trials

Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer

NTRK
Start date: July 26, 2021
Phase:
Study type: Observational

This multi-center study aims at NTRK fusion testing of all patients with advanced thyroid cancer (any histotype and regardless of stage). The primary objective of this study is to assess the frequency of NTRK fusions in thyroid cancer. The secondary objective of this study is to develop an effective tool (testing) strategy for the detection of NTRK fusions in thyroid tumors, comparing the diagnostic tecniques available (IHC, real-time PCR and NGS).

NCT ID: NCT05579782 Active, not recruiting - Thyroid Cancer Clinical Trials

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy

Start date: October 5, 2022
Phase: N/A
Study type: Interventional

This study describes a single center, randomized, single-blinded clinical trial to assess the clinical benefits of the use of near infrared autofluorescence (NIRAF) detection with an FDA-cleared device 'Parathyroid Eye (PTeye)' for identifying parathyroid glands during total thyroidectomy. It compares risk-benefits and outcomes in patients undergoing total thyroidectomy where NIRAF detection with PTeye for parathyroid identification is either used or not used.

NCT ID: NCT05328076 Active, not recruiting - Thyroid Cancer Clinical Trials

Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography

ANGIO_PARA
Start date: May 2, 2022
Phase:
Study type: Observational

Prospective, observational, single-center study about the use of indocyanine green angiography during total thyroidectomy. The main objective of the study is to identify a quantitative score of parathyroid vascularization as an outcome of angiography that correlates with the absence of postoperative hypoparathyroidism. It is planned to enroll 66 patients.

NCT ID: NCT05131815 Active, not recruiting - Breast Cancer Clinical Trials

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Start date: January 10, 2022
Phase: N/A
Study type: Interventional

The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors. AYAs who were diagnosed with cancer and have completed cancer treatment will be recruited for this study. This study will enroll 20 participants in total and will last approximately 3 months.

NCT ID: NCT04896580 Active, not recruiting - Breast Cancer Clinical Trials

IIT2020-20-SHIRAZIP-WALK: Nature Walks

Start date: June 21, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to examine whether nature-based activities provide benefits for breast cancer survivors. The investigators want to know whether a nature-based exercise program is feasible. Women who were diagnosed with breast cancer and have completed cancer treatment will be recruited for the main study. The main study will enroll up to 20 breast cancer subjects in total. This intervention will also include a sub-study examining the same outcomes among adolescents and young adult (AYA) subjects who were diagnosed with cancer (any type) and have completed cancer treatment. The sub-study will enroll up to 20 AYA (ages 18-39) subjects.

NCT ID: NCT04552769 Active, not recruiting - Thyroid Cancer Clinical Trials

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Start date: September 10, 2020
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy of treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid

NCT ID: NCT04544111 Active, not recruiting - Thyroid Cancer Clinical Trials

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Start date: September 2, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.

NCT ID: NCT04521348 Active, not recruiting - Thyroid Cancer Clinical Trials

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

Start date: December 30, 2019
Phase: Phase 2
Study type: Interventional

The study is being conducted to evaluate the safety and efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody in subjects with advanced thyroid cancer.

NCT ID: NCT04495985 Active, not recruiting - Thyroid Cancer Clinical Trials

CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer

Start date: July 14, 2020
Phase:
Study type: Observational

Radioactive iodine (RAI) is a radioisotope used to ablate thyroid gland remnant after thyroidectomy in patients diagnosed with differentiated thyroid carcinoma (DTC). A whole body scan (WBS) is performed to not only evaluate for iodine uptake by the native thyroid tissue but also to observe for uptake in other areas of the body, which could be physiological or indicative of iodide-avid metastases. Research has shown a correlation between breast cancer and thyroid cancer. Patients with DTC have been found to have elevated levels of serum prolactin, which could lead to mammary gland dysfunction. In patients with DTC undergoing RAI scanning or therapy, it has been previously observed that patients prepared by thyroid hormone withdrawal have significantly higher breast uptake on whole body scan compared to those prepared by rh-TSH. Considering the impact of prolactin on breast tissue, this study aims to correlate these findings with the lab values and the method of preparation. Accordingly, the research question is as follows: does the method of WBS preparation impact prolactin levels and how does that correlate with breast uptake in patients with DTC undergoing RAI WBS?